Cancer Control Program
Description of the Program
The overall mission of the Cancer Control Program (CC) is to reduce the incidence, promotion and progression of cancer, to minimize disease morbidity and mortality, and optimize quality of life. The program includes high impact translational science; a focus on understanding and attenuating disparity in disease risk and outcomes; and the ability to access and affect unique populations in our catchment area and beyond.
The program is led by Dr. Erin Kobetz. Members represent multiple University departments and disciplines, including communications, education, engineering, epidemiology and public health sciences, microbiology/immunology, medical oncology, pediatrics, psychology, and psychiatry. The membership is balanced across basic, population and clinical research.
Goals of the Program
With an emphasis on diverse populations and a goal of reducing cancer disparities in our catchment area, program themes and corresponding aims are as follows:
Cancer Risk Factors and Conditions Specific Aims:
- To identify innate and modifiable risk factors and risk conditions (e.g., genetic, behavioral, cultural, and environmental) associated with cancer onset and progression.
- Using community-engaged methodologies to evaluate biologic, enteromic, cognitive, cultural and environmental determinants of cancer risk.
- To develop and validate innovative screening modalities for prevention and detection of cancer in high-risk groups.
Prevention and Early Detection Specific Aims:
- To improve cancer prevention, increase early detection, and reduce cancer mortality.
- Using a bio-psychosocial approach to understand and intervene on cancer risk behaviors.
- Develop and evaluate culturally specific interventions to improve prevention and screening outcomes.
Adaptation to Cancer Treatment and Survivorship Specific Aims:
- To understand and promote adaptation to cancer treatment and survivorship across the life course.
- To identify predictors (Bio-Behavioral-Psychosocial) of adaptation to primary treatment and survivorship in diverse populations.
- To develop novel Bio-Behavioral-Psychosocial intervention modalities to facilitate adaptation and optimal response to cancer treatment and survivorship treatment.
CC will accomplish such aims through high impact, translational research, which addresses the unique needs of our catchment area from cancer prevention to survivorship.
- Maria T. Abreu, M.D.
- Michael Antoni, Ph.D.
- Daniel F. Armstrong, Ph.D.
- Margaret M. Byrne, Ph.D.
- Olveen Carrasquillo, M.D.
- Charles Carver, Ph.D.
- Xi Chen, Ph.D.
- Sara J. Czaja, Ph.D.
- Judith DeLeo Hurley, M.D.
- Sapna Deo, Ph.D.
- Elizabeth J. Franzmann, M.D.
- Sophia George, Ph.D.
- W. Jarrard Goodwin, M.D., F.A.C.S.
- Jennifer J. Hu, Ph.D.
- Amishi P. Jha, Ph.D.
- Youngmee Kim, Ph.D.
- Suzanne C. Lechner, Ph.D.
- David J. Lee, Ph.D.
- Roy C. Levitt, M.D.
- Erin N. Marcus, M.D., M.P.H.
- Charles Nemeroff, M.D., Ph.D.
- J. Sunil Rao, Ph.D.
- Neil Schneiderman, Ph.D.
- Brian Slomovitz, M.D.
- Richard J. Thurer, M.D.
- Michal Toborek, M.D., Ph.D.
- Monica Webb Hooper, Ph.D.
- Roy E. Weiss, M.D., Ph.D.
- Raphael L. Yechieli, M.D.